Douglas Hawkins
0000-0003-3602-1375
15 papers found
Refreshing results…
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
Germline Genetic Variants and Pediatric Rhabdomyosarcoma Outcomes: A Report from the Children’s Oncology Group
Genome-Wide Association Study Identifies ROBO2 as a Novel Susceptibility Gene for Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors
Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe
Congenital spindle cell rhabdomyosarcoma: An international cooperative analysis
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial
An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer
Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium
Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group
Germline Cancer-Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report from the Children’s Oncology Group
Survival outcomes of patients with localized FOXO1 fusion‐positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
The HDAC3–SMARCA4–miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma
Missing publications? Search for publications with a matching author name.